Treating Diabetic Dyslipidemia: A Deep Dive into PCSK9 Inhibitors

Treating Diabetic Dyslipidemia: A Deep Dive into PCSK9 Inhibitors is organized by Vindico Medical Education.

 

Release Date: 8/17/2018

Expiration Date: 8/16/2019

 

The intended audience for this activity is endocrinologists and other health care professionals involved in the treatment of patients with diabetic dyslipidemia.

 

This CME Conference has been approved for a maximum of 1.0 AMA PRA Category 1 Credits™.

 

Diabetes mellitus is associated with considerable increased risk of atherosclerotic cardiovascular disease. Lowering low-density lipoprotein cholesterol (LDL-C) plays an important role in therapeutic strategies designed to reduce cardiovascular risk. Nevertheless, 1 in 7 patients with diabetes, who are treated with statins, will experience a cardiovascular event within 5 years on treatment. Residual clinical risk has been demonstrated in statin trials, suggesting that additional therapy is required to achieve enhanced, effective prevention of cardiovascular disease. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have demonstrated the ability to lower LDL-C, reduce LDL particle number, and decrease cardiovascular events. This educational activity will review the latest data regarding the management of dyslipidemia in patients with diabetes, as well as assess the newly released data regarding the safety, efficacy, and reduction of adverse cardiovascular outcomes with PCSK9 inhibitor therapy.

 

Upon successful completion of this activity, participants should be better able to:

• Summarize recent advances in the understanding of the pathogenesis of diabetic dyslipidemia.

• Describe how the underlying pathophysiology of diabetic dyslipidemia can be used to direct therapy.

• Incorporate non-LDL-C markers into clinical decision making when evaluating cardiovascular risk in patients with diabetes.

• Apply recent clinical data on the use of established and emerging lipid-lowering agents for the treatment of diabetic dyslipidemia.